# NCT06053658 (NCT06053658)

> Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06053658
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Renal Cell Carcinoma
- Interventions: Tivozanib; Nivolumab
- Enrollment: 48
- Primary outcome: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 16
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06053658

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06053658", "email": "<work email>"}; the inbox owner confirms by the emailed link.